Roche (RHHBY) reported that its fiscal 2024 IFRS net income decreased by 19%, or 26% in Swiss francs, to 9.2 billion francs, mainly ...

Vandana Singh Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received ... Poseida - equivalent to 66% of the California company's stock - which had been tendered by shareholders at a price ...

ROCHE HOLDING AG (ADR) (RHHBY) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock ...

I hope to see you there. Analyst’s Disclosure: I/we have a beneficial long position in the shares of RHHBY either through stock ownership, options, or other derivatives. I wrote this article ...

This week, Roche RHHBY announced that it will acquire its ... (See the last pharma stock roundup here: Pharma Stock Roundup: EU Nod for PFE’s Hympavzi, NVS Ups Sales View) What's Next in the ...

Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...

Short interest in Roche Holding AG (OTC:RHHBY) increased during the last reporting ... are betting on the decline of Roche Holding's stock. Short interest data is updated every two weeks.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Poseida Therapeutics (PSTX) will cease trading on Nasdaq after the merger and will become a wholly owned subsidiary of Roche (OTCQX:RHHBY). PSTX stock price traded marginally higher, up 0.42% to $ ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.